|
1.
|
Dobner BC, Riechardt AI, Joussen AM,
Englert S and Bechrakis NE: Expression of haematogenous and
lymphogenous chemokine receptors and their ligands on uveal
melanoma in association with liver metastasis. Acta Ophthalmol.
90:e638–e644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Petousis V and Finger PT: Current methods
for the diagnosis and treatment of choroidal melanoma. US
Ophthalmic Rev. 5:62–69. 2012.
|
|
3.
|
Woodman SE: Metastatic uveal melanoma:
biology and emerging treatments. Cancer J. 18:148–152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Barak V, Pe'er J, Kalickman I and Frenkel
S: VEGF as a biomarker for metastatic uveal melanoma in humans.
Curr Eye Res. 36:386–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kvanta A, Steen B and Seregard S:
Expression of vascular endothelial growth factor (VEGF) in
retinoblastoma but not in posterior uveal melanoma. Exp Eye Res.
63:511–518. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Musumeci F, Radi M, Brullo C and Schenone
S: Vascular endothelial growth factor (VEGF) receptors: drugs and
new inhibitors. J Med Chem. 55:10797–10822. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Erdei E and Torres SM: A new understanding
in the epidemiology of melanoma. Expert Rev Anticancer Ther.
10:1811–1823. 2010. View Article : Google Scholar
|
|
8.
|
El Filali M, van der Velden PA, Luyten GP
and Jager MJ: Anti-angiogenic therapy in uveal melanoma. Dev
Opthalmol. 49:117–136. 2012.PubMed/NCBI
|
|
9.
|
Spagnolo F, Caltabiano G and Queirolo P:
Uveal melanoma. Cancer Treat Rev. 38:549–553. 2012. View Article : Google Scholar
|
|
10.
|
Franco R, Botti G, Mascolo M, et al:
CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression.
Front Biosci (Elite Ed). 2:13–21. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Berse B, Brown LF, Van De Water L, Dvorak
HF and Senger DR: Vascular permeability factor (vascular
endothelial growth factor) gene is expressed differentially in
normal tissues, macrophages, and tumors. Mol Biol Cell. 3:211–220.
1992. View Article : Google Scholar
|
|
12.
|
Stitt AW, Simpson DA, Boocock C, Gardiner
TA, Murphy GM and Archer DB: Expression of vascular endothelial
growth factor (VEGF) and its receptors is regulated in eyes with
intra-ocular tumours. J Pathol. 186:306–312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sheidow TG, Hooper PL, Crukley C, Young J
and Heathcote JG: Expression of vascular endothelial growth factor
in uveal melanoma and its correlation with metastasis. Br J
Ophthalmol. 84:750–756. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Perrone G, Santini D, Vincenzi B, Zagami
M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C,
Vetrani A, Tonini G and Rabitti C: COX-2 expression in DCIS:
correlation with VEGF, HER-2/neu, prognostic molecular markers and
clinicopathological features. Histopathology. 46:561–568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Schori H, Kipnis J, Yoles E, WoldeMussie
E, Ruiz G, Wheeler LA and Schwartz M: Vaccination for protection of
retinal ganglion cells against death from glutamate cytotoxicity
and ocular hypertension: implications for glaucoma. Proc Natl Acad
Sci USA. 98:3398–3403. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Damato BE, Paul J and Foulds WS:
Predictive factors of visual outcome after local resection of
choroidal melanoma. Br J Ophthalmol. 77:616–623. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Schwarz MA and Cleaver OB: Development of
the pulmonary endothelium in development of the pulmonary
circulation: vasculogenesis and angiogenesis. The Pulmonary
Endothelium: Function in Health and Disease. Voelkel NF and Rounds
S: 1st edition. Wiley-Blackwell; Chichester: pp. 3–24. 2009
|
|
18.
|
Ding GX, Feng CC, Song NH, et al:
Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia
are, respectively, related to vascular endothelial growth factor
(VEGF) expression in renal clear cell carcinoma. Urol Oncol. Apr
23–2012.(Epub ahead of print).
|
|
19.
|
Ugurel S, Rappl G, Tilgen W and Reinhold
U: Increased serum concentration of angiogenic factors in malignant
melanoma patients correlates with tumor progression and survival. J
Clin Oncol. 19:577–583. 2001.PubMed/NCBI
|
|
20.
|
Clarijs R, Schalkwijk L, Ruiter DJ and de
Waal RM: Lack of lymphangiogenesis despite coexpression of VEGF-C
and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis
Sci. 42:1422–1428. 2001.PubMed/NCBI
|
|
21.
|
Boyd SR, Tan DS, de Souza L, et al: Uveal
melanomas express vascular endothelial growth factor and basic
fibroblast growth factor and support endothelial cell growth. Br J
Ophthalmol. 86:440–447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wang FH, Li B, Sun XL, et al: Correlation
of tumor angiogenesis with clinicopathologic prognostic parameters
in choroidal melanoma. Chin J Ophthalmol. 39:68–72. 2003.(In
Chinese).
|
|
23.
|
Sahin A, Kiratli H, Tezel GG, Soylemezoglu
F and Bilgic S: Expression of vascular endothelial growth factor A,
matrix metalloproteinase 9 and extravascular matrix patterns in
iris and ciliary body melanomas. Ophthalmic Res. 39:40–44. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zhao XJ, Li B, Li LQ, Gao F and Sun XL:
Relationship of survivin and VEGF with angiogenesis in choroidal
melanoma. Chin Ophthal Res. 27:770–773. 2009.(In Chinese).
|
|
25.
|
Xu Q, Zhao GQ, Zhao J, et al: Expression
and significance of factors related to angiogenesis in choroidal
melanoma. Int J Ophthalmol. 4:49–54. 2011.PubMed/NCBI
|
|
26.
|
Pang X, Yunhui Q and Yuewe M: Expressions
of A disintegrin and metalloproteinase 9 and vascular endothelial
growth factor in ocular malignant melanomas. Rec Adv Ophthalmol.
32:620–623. 2012.(In Chinese).
|
